A clinical study to identify biomarkers for determining the malignant potential of ovarian immature teratoma

A clinical study to identify biomarkers for determining the malignant potential of ovarian immature teratoma - A clinical study to identify biomarkers for determining the malignant potential of ovarian immature teratoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046404

Enrollment

200

Registered

2022-03-18

Start date

2021-11-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients who underwent surgical removal of immature teratoma of the ovary during the 20-year period between January 2001 and December 2020. Patients whose HE-stained and formalin-fixed paraffin-embedded specimens of the excised tumor are preserved at the treating institution.

Exclusion criteria

Exclusion criteria: Patients with mixed tumors with other malignant germ cell tumors. Patients who have expressed their refusal to partici pate in the study. Patients who are judged by the principal investigator or sub-investigator to be inappropriate for participation in this study.

Design outcomes

Primary

Measure	Time frame
Oct4 expression by immunohistochemical staining. Recurrence within 1 year after surgery	—

Secondary

Measure	Time frame
Grade of immature teratoma by central pathological diagnosis. Factors influencing prognosis: age, FIGO stage, surgical procedure, and adjuvant chemotherapy. Adjuvant chemotherapy and number of cycles 1)Recurrence free survival,2) Overall survival	—

Countries

Japan

Contacts

Public ContactKaoru Abiko

NHO Kyoto Medical Center Clinical Research Center / Obstetrics and Gynecology

kaoruvc@gmail.com075-641-9161

Outcome results